About the Magenta Study

The Study of Genetic Testing from Your Living Room.

The MAGENTA study aims to improve availability of genetic testing for hereditary cancer syndromes to at-risk individuals through the use of an online genetic testing service. Our hope is that making genetic testing accessible, without requiring them to travel to their healthcare provider, will save more lives by preventing cancer in women found to be at an increased risk of getting it.

Participation in this trial will not require any travel, but will require access to the internet and phone.

Study Requirements

Participants who qualify for this study will fill out personal and family health history information, undergo genetic testing (saliva sample) for 19 genes associated with inherited cancer risk, and complete a series of online questionnaires regarding their experience. Some individuals in this study will undergo genetic counseling over the phone; others not. For more information on study requirements, please review the MAGENTA Study Timeline below.

* The 19-gene panel includes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MSH2, MSH6, MLH1, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, and STK11.

Eligible Participants

• Are over the age of 30
• Are able to read and speak English
• Have a valid mailing address in the U.S.
• Have a personal or family history of breast cancer OR a family history of ovarian cancer (no personal history of ovarian cancer allowed)
• Have at least one ovary
• Have never had genetic testing or counseling for cancer risk in the past
• Are willing to undergo genetic testing (at no cost) and share their results with their healthcare provider
• Are willing to complete a series of questionnaires for up to two years

Questions about the Study?

Media Inquiries

For all media inquiries, please contact Rebecca Lechner at (612) 822-0500 or via e-mail at rlechner@mnovarian.org.

A Collaborative Research Effort

The MAGENTA study is supported by the Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team .